» Articles » PMID: 17158411

Effect of Lifestyle Intervention on Metabolic Coronary Heart Disease Risk Factors in Obese Older Adults

Overview
Journal Am J Clin Nutr
Publisher Elsevier
Date 2006 Dec 13
PMID 17158411
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Coronary heart disease (CHD) risk factors increase with age and body mass index (BMI; in kg/m2). However, whether lifestyle intervention ameliorates metabolic CHD risk factors in obese older adults is unknown.

Objective: The objective was to determine whether lifestyle intervention improves metabolic CHD risk factors in obese older adults.

Design: A 6-mo outpatient randomized controlled trial was conducted in obese (BMI >or= 30) older (>or=65 y) adults randomly assigned to diet and exercise therapy (treatment group; n = 17) or no therapy (control group; n = 10). The main outcomes were CHD risk factors.

Results: Body weight decreased by 8.4% (8.2 kg) in the treatment group; weight did not change significantly (0.7 kg) in the control group (P < 0.001 between groups). Changes between the control and treatment groups, respectively, in waist circumference (1 and -10 cm), plasma glucose (4 and -4 mg/dL), serum triacylglycerols (0 and -45 mg/dL), and systolic (-2 and -10 mm Hg) and diastolic (0 and -8 mm Hg) blood pressure were different (P < 0.05 for all). The number of subjects with the metabolic syndrome decreased by 59% in the treatment group but did not change significantly in the control group (P < 0.05). Serum free fatty acids increased by 10 micromol/L in the control group and decreased by 99 micromol/L in the treatment group (P < 0.05). Changes between the control and treatment groups, respectively, in C-reactive protein (0.8 and -2.5 mg/L) and interleukin 6 (1.6 and -2.4 pg/mL) were different (P < 0.05 for both).

Conclusions: Lifestyle intervention decreases multiple metabolic CHD risk factors simultaneously in obese older adults.

Citing Articles

Differentials in lifestyle practices and determinants among hypertensive adults from three geopolitical zones in Nigeria.

Salawu M, Erakhaiwu J, Bamgboye E, Jalo R, Ogah O, Oyewole O Pan Afr Med J. 2024; 48:98.

PMID: 39492855 PMC: 11530389. DOI: 10.11604/pamj.2024.48.98.40776.


Body mass index and sarcopenia and mortality risk among older hypertensive outpatients; the Nambu Cohort Study.

Inoue T, Matsuoka M, Tamashiro M, Arasaki O, Arima H Hypertens Res. 2024; 48(2):744-753.

PMID: 39394516 DOI: 10.1038/s41440-024-01921-2.


Secondary integrated analysis of multi-tissue transcriptomic responses to a combined lifestyle intervention in older adults from the GOTO nonrandomized trial.

Bogaards F, Gehrmann T, Beekman M, Lakenberg N, Suchiman H, de Groot C Nat Commun. 2024; 15(1):7013.

PMID: 39147741 PMC: 11327278. DOI: 10.1038/s41467-024-50693-3.


Obesity pharmacotherapy in older adults: a narrative review of evidence.

Henney A, Wilding J, Alam U, Cuthbertson D Int J Obes (Lond). 2024; .

PMID: 38710803 DOI: 10.1038/s41366-024-01529-z.


Metabolic Effects of Testosterone Added to Intensive Lifestyle Intervention in Older Men With Obesity and Hypogonadism.

Gonzalez-Gil A, Barnouin Y, Celli A, Viola V, Villarreal M, Nava M J Clin Endocrinol Metab. 2024; 110(3):e814-e826.

PMID: 38606934 PMC: 11470114. DOI: 10.1210/clinem/dgae249.